4th Quarter - Report

ACADIA PHARMACEUTICALS for ACADIA PHARMACEUTICALS

Period 4th Quarter 2025 Filed Jan 19, 2026 Signed by Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals

Official filing
Firm
ACADIA PHARMACEUTICALS
Client
ACADIA PHARMACEUTICALS
Income
—
Expenses
$590,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.

LobbyistCovered position, as disclosed
MICHAEL MATTOON —
SARAH TODD TELLOCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1492 (119th), H.R. 1 (119th), H.R. 946 (119th), H.R. 1509 (119th)

Taxation/Internal Revenue Code TAX

Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).

LobbyistCovered position, as disclosed
MICHAEL MATTOON —
SARAH TODD TELLOCK —

Contacted: Treasury, Dept of; SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1414 (119th), H.R. 1 (119th)

Health Issues HCR

Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.

LobbyistCovered position, as disclosed
MICHAEL MATTOON —
SARAH TODD TELLOCK —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1 (119th), H.R. 1262 (119th), H.R. 3731 (119th), H.R. 1509 (119th), H.R. 946 (119th), H.R. 1414 (119th), H.R. 1492 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.